Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Techniques & Tools

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma & Biopharma
    • Omics
    • Forensics
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2024 / Articles / Nov / The Synergy of Science and Business
Manufacture Advanced Medicine Supply Chain Supply Chain

The Synergy of Science and Business

Developing science is good; developing successful commercialization strategies is great.

By Stella Vnook 11/07/2024 3 min read

Share

Science is at the heart of cell and gene therapies, but business strategy is the lifeblood that ensures its survival and success. As a former healthcare provider and scientist with over 25 years of experience in biotechnology and pharmaceuticals, I learned early on that scientific breakthroughs alone do not guarantee market success. After transitioning into leadership roles, I realized that developing and executing the right business strategies is critical, particularly in a landscape like CGT where investment is scarce, competition is fierce, and failure is not an option. For innovation to shine in the real world, it must be paired with a robust understanding of business drivers, market needs, and strategic planning.

Since taking the lead at Likarda, my objective has been to fully harness the power of cutting-edge technology by aligning a thoughtful business strategy of encapsulating cells and delivering them effectively. The science is groundbreaking, but it was the revised strategic approach that realized the potential. By analyzing market trends, evaluating unmet needs, and taking a hard look at where resources and investments were headed, I began to see broader applications based on the versatility of the technology, which we positioned in cell therapies, biologics, small molecules, and even cryopreservation logistics. Diversifying our product pipeline also ensured that we weren't dependent on a single market segment.

The key strategic pillars that every scientist or entrepreneur should embrace when venturing into the commercial world are:

Knowing the market needs and gaps
 

Hypothesis generation is crucial in business strategy. You need to continually ask: “What do patients, clinicians, or industry leaders need that isn't being met?” Understanding the broader healthcare ecosystem and identifying the true pain points is critical to shaping a product or technology that will stand out. For Likarda, a deep-dive into unmet needs led us to understand that our Core-Shell Spherification technology had the potential to disrupt multiple sectors.

Expanding your view beyond your original vision
 

Once you have proof-of-concept, it's essential to ask "What else?" Expanding applications into new markets is a vital business strategy, especially when resources are limited. In the CGT space, funding often falls short. Having a diversified approach allows companies to build resilience.

Assessing the financial landscape early and often
 

Every entrepreneur needs to learn the language of finance. Knowing how to read a balance sheet, understanding capital efficiency, and projecting ROI are just as important as understanding the science behind your technology. Set realistic financial goals, secure the right funding partners, and deploy resources wisely.

Anticipating market shifts and adapt
 

A business model that works today might not work tomorrow. Whether it is regulatory shifts, technological advancements, or emerging competition, you must stay nimble. Be prepared to pivot to a platform play to avoid becoming a one-product company.

Focusing on execution and scalability
 

Every great scientific breakthrough must eventually commercialize to benefit society. Can you manufacture at scale? Can you deliver consistent results across different markets? Ensure you have the operational infrastructure in place and think about the path to commercialization early on.

Building strategic partnerships
 

Forming partnerships with larger corporations, academic institutions, or even competitors can help you scale faster and more efficiently. For instance, our collaboration with pharma companies and other partners allowed us to explore new pipelines while leveraging their expertise and resources.

In closing, successful leadership in the cell and gene therapy (CGT) space demands more than scientific acumen—it requires a fusion of visionary strategy and practical business insights. By knowing the market’s unmet needs, diversifying the applications of core technology, maintaining financial discipline, anticipating shifts, and forming strategic partnerships, we not only position our company to thrive but also ensure that the innovations we pioneer have the greatest possible impact on patients’ lives. These strategies collectively form a roadmap for bringing therapies to market that are not only groundbreaking in their science but sustainable in their execution. At the heart of all we do remains the ultimate goal: delivering transformative, life-improving solutions to patients worldwide. In this fast-paced and competitive landscape, it is this blend of science and strategy that will define the leaders of tomorrow.

By combining cutting-edge technology with strong business foundations, we don't just aim to survive—we aim to shape the future of medicine.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Stella Vnook

CEO, Likarda

More Articles by Stella Vnook

False

Advertisement

Recommended

False

Related Content

Don’t Forget CDx Developers
Advanced Medicine
Don’t Forget CDx Developers

November 7, 2014

0 min read

Many drug developers are going ‘full steam ahead’ with personalized medicine strategies. They would be wise to consider a more equitable business model for an essential partner in the process: the developer of the companion diagnostic.

The Next Decade of Cell and Gene Therapies
Advanced Medicine Bioprocessing - Upstream & Downstream Trends & Forecasts Digital Technologies
The Next Decade of Cell and Gene Therapies

May 7, 2025

5 min read

Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.

Peter Marks Resigns from FDA
Standards & Regulation Profession Vaccines Advanced Medicine
Peter Marks Resigns from FDA

April 1, 2025

3 min read

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”

The Trump Effect on Cell and Gene: Science versus Shockwaves
Business Practice Standards & Regulation Trends & Forecasts Advanced Medicine
The Trump Effect on Cell and Gene: Science versus Shockwaves

April 1, 2025

9 min read

Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.